Aptuit And Chiesi Collaborate To Treat Idiopathic Pulmonary Fibrosis

News   Jan 05, 2017 | Original story from Aptuit

 
Aptuit And Chiesi Collaborate To Treat Idiopathic Pulmonary Fibrosis
 
 
 

RELATED ARTICLES

Existing 20-year-old Multiple Sclerosis Drug Effective Against Multi-resistant Bacteria

News

A widely-used and twenty-year-old medicine used to treat multiple sclerosis can also beat a type of multi-resistant bacteria for which there are currently only a few effective drugs.

READ MORE

Novel Chemistry Technique Simplifies Late-Stage Modification of Drug Compounds

News

Chemists at The Scripps Research Institute (TSRI) have invented a technique that overcomes a long-standing problem in organic chemistry and should streamline the process of discovery and development for many new drugs.

READ MORE

Pre-Diabetes Discovery Marks Step Towards Precision Medicine

News

Identification of three molecules that can be used to accurately assess pre-diabetes – a key predictor of conditions such as diabetes and high blood pressure – has brought precision medicine for humans a step closer.

READ MORE

 

Comments | 1 ADD COMMENT

Ana Aitawa | Oct 03, 2017

The global idiopathic pulmonary fibrosis treatment market expected to reach US$ 3.5 billion by 2021, growing at CAGR 14.4% over the forecast period 2017-2021, owing to increasing drug prices and rapid approval of new treatments. Visit Idiopathic Pulmonary Fibrosis (IPF) Treatment Market by Treatment Type – Pharmacological Treatment (Pirfenidone (Esbriet), Nintedanib (Ofev), Generic Pirfenidone); Non-pharmacological Treatment (Oxygen Therapy, Pulmonary Rehabilitation, Mechanical Ventilation, Lung Transplantation, Other Non-Pharmacological Treatment); Patients by Disease Severity (Mild, Moderate, Severe); Drug Pipeline Analysis (AEOL-10150, Lebrikizumab, Tipelukast, Tralokinumab, FG-3019, Simtuzumab, BMS-986020, AF-219, SAR156597, BG00011, PRM-151, PBI-4050) at https://www.ihealthcareanalyst.com/report/idiopathic-pulmonary-fibrosis-treatment-market/


To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE